Table 2.
Recurrence rates of hepatobiliary and pancreatic (HBP) cancers after surgical resection, in Phase III randomized controlled trials (RCTs) or retrospective studies.
| Type of Cancer | Treatment | Recurrence Rate (%) |
|---|---|---|
| HCC | Hepatectomy | 51% [67]; 54% [65]; 63% [68] |
| HCC | OLT | 7.6% [69]; 15.3% [66]; 18.3% [70] |
| PDA | Pancreatectomy and adjuvant chemotherapy | 75%–85% [71]; 81%–93% (Phase III RCT) [48] |
| ICC | Resection | 62.2% [72]; 70% [73] |
| Mixed HCC-CC/ICC Hilar/ICC | OLT | 60% [74]; 38% [75] |
| ECC | ||
| Distal | Resection | 39% [76] |
| Hilar | Resection, OLT | 53% [77]; 68% [78]; After OLT: 20% [79] |
| GBC | Resection, resection and adjuvant chemotherapy | 66% [78]; 81.4% [80] |
HCC: hepatocellular carcinoma; OLT: orthotopic liver tranplantation; PDA: pancreatic ductal adenocarcinoma; ICC: intrahepatic bile duct cholangiocarcinoma; HCC-CC: hepatocellular cholangiocarcinoma; ECC: extrahepatic bile duct cholangiocarcinoma; GBC: gallbladder cancer.